Skip to main content

Indi Molecular Collaborating with Sigma-Aldrich on PCC Reagents

NEW YORK (GenomeWeb) – Indi Molecular said today that it has entered into a co-development deal with Sigma-Aldrich to explore the use of Indi Molecular's PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of biological reagents.

The project will analyze using the PCC agents, which are synthetic peptides capable of protein binding with similar performance to traditional antibodies and with potentially lower development times and costs, for protein research.

"Indi’s PCC technology is a promising technology that we believe may play an important role in designing cutting-edge biological tools," Patrick Sullivan, vice president, research & development at Sigma-Aldrich, said in a statement.

Indi Molecular, which was launched as a spinout from its parent company Integrated Diagnostics in 2013, also aims to develop the molecules as reagents for applications including in vivo imaging, in vitro diagnostics, and as therapeutics.

Financial and other terms of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.